# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
AbbVie (NYSE:ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Us...
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractor...
Celsius' CEL383 is a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody for th...
AbbVie received an FDA Complete Response Letter for ABBV-951 (foscarbidopa/foslevodopa) due to third-party manufacturing issues...
U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for ABBV-951 based on observations from an inspec...